Absci Corporation

ABSI

US00091E1091

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-03 pm EDT			5-day change	1st Jan Change
5.08 ^USD	+2.01%		+10.92%	+20.95%

Mar. 21	Earnings Flash (ABSI) ABSCI CORPORATION Reports Q4 Revenue $338,000	MT
Mar. 21	Absci Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Absci Corporation(NasdaqGS:ABSI) added to S&P TMI Index

September 20, 2021 at 12:00 am EDT

Latest news about Absci Corporation

Earnings Flash (ABSI) ABSCI CORPORATION Reports Q4 Revenue $338,000	Mar. 21	MT
Absci Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 21	CI
Absci Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 21	CI
Scotiabank Starts Absci With Sector Outperform Rating, $13 Price Target	Mar. 14	MT
KeyBanc Raises Price Target on Absci to $8 From $5, Keeps Overweight Rating	Mar. 04	MT
Absci Initiates IND-Enabling Studies for Abs-101, A Potential Best-In-Class Anti-Tl1a Antibody De Novo Designed and Optimized Using Generative Ai	Feb. 21	CI
Transcript : Absci Corporation Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 10:30 AM	Jan. 11
HC Wainwright Raises Absci's Price Target to $7 From $4, Buy Rating Kept	Jan. 08	MT
Absci Corporation to Present Preclinical Data for ABS-101, A Potential Best-In-Class Anti-TL1A Antibody Development Program, at 42nd Annual J.P. Morgan Healthcare Conference	Jan. 08	CI
Absci, PrecisionLife to Develop AI-Enabled Drug Pipeline	Dec. 20	MT
Sector Update: Health Care	Dec. 20	MT
Absci Corporation and PrecisionLife Announce Strategic R&D Partnership to Jointly Develop AI-Enabled Drug Pipeline	Dec. 20	CI
Absci Corporation(NasdaqGS:ABSI) dropped from NASDAQ Biotechnology Index	Dec. 15	CI
Absci Corporation Appoints Menelas Pangalos as Class II Director and Member of Compensation Committee of the Board, Effective January 1, 2024	Dec. 07	CI
KeyBanc Initiates Absci at Overweight With $3 Price Target, Calls Valuation 'Attractive' Given New Drug Programs, Partnerships	Dec. 05	MT
AstraZeneca: AI collaboration with Absci	Dec. 04	CF
Absci Shares Rise 27% After Announcing Collaboration With AstraZeneca	Dec. 04	DJ
Sector Update: Health Care Stocks Lean Lower Pre-Bell Monday	Dec. 04	MT
Sector Update: Health Care	Dec. 04	MT
Absci Working With AstraZeneca to Use AI Platform to Discover Oncology Candidate	Dec. 04	MT
Absci Corporation Announces Collaboration with Astrazeneca to Advance Ai-Driven Oncology Candidate	Dec. 04	CI
UK Stocks-Factors to watch on Dec 4	Dec. 04	RE
AstraZeneca, Absci Enter $247 Million Partnership to Develop New Cancer Treatment	Dec. 03	MT
AstraZeneca, AI biologics firm Absci tie up on cancer drug - FT	Dec. 03	RE
AstraZeneca ties up with AI biologics company to develop cancer drug - FT	Dec. 03	RE

Absci Corporation is a generative artificial intelligence (AI) drug creation company. The Company combines AI with scalable wet lab technologies to create biologics for patients. It has built an Integrated Drug Creation platform to identify novel drug targets, discover biotherapeutic candidates, and generate the cell lines to manufacture them in a single process. The Company uses its platform to predict, identify, design, construct, screen, select and scale production of biologic drug candidates for its partners, and learn from the data it generates. Its SoluPro technology is a multiplex synthetic biology approach that overcomes the limitations of highest-throughput automation labs. The Company supports its generative AI designs with its wet lab's high-throughput functional validation capabilities. It reconstructs prevalent immune-response molecules, such as antibodies from disease tissue and identify their corresponding antigens, offering new therapeutic targets.

Sector

Biotechnology & Medical Research

Calendar

2024-05-13 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Absci Corporation

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

5.08 USD

Average target price

8.628 USD

Spread / Average Target

+69.84%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ABSCI CORPORATION	+20.95%	574M
MODERNA, INC.	+25.69%	47.9B
LONZA GROUP AG	+46.90%	41.42B
IQVIA HOLDINGS INC.	-3.46%	40.7B
CELLTRION, INC.	-6.20%	28.92B
ICON PUBLIC LIMITED COMPANY	+9.17%	25.55B
ALNYLAM PHARMACEUTICALS, INC.	-20.42%	19.27B
BIO-TECHNE CORPORATION	+0.17%	12.15B
MEDPACE HOLDINGS, INC.	+28.07%	12.14B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.24%	11.99B

Other Biotechnology & Medical Research